# Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

> **NCT02322229** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 62 (actual)

## Conditions studied

- Vitreomacular Traction
- Vitreomacular Adhesion

## Interventions

- **DRUG:** Ocriplasmin 0.125 mg in a 0.1 mL volume

## Key facts

- **NCT ID:** NCT02322229
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-26
- **Primary completion:** 2015-12-11
- **Final completion:** 2016-05-09
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322229, "Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02322229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*